Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy

Author:

Amatya Reeju1,Lee Donghee1,Min Kyoung Ah2ORCID,Shin Meong Cheol1ORCID

Affiliation:

1. College of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, 501 Jinju Daero, Jinju 52828, Republic of Korea

2. College of Pharmacy and Inje Institute of Pharmaceutical Sciences and Research, Inje University, 197 Injero, Gimhae 50834, Republic of Korea

Abstract

Nonalcoholic fatty liver disease (NAFLD) has become globally prevalent and is the leading cause of chronic liver disease. Although NAFLD is reversible without medical intervention in the early stage, the condition could be sequentially worsened to nonalcoholic steatohepatitis (NASH) and, eventually, cirrhosis and hepatic cancer. The progression of NAFLD is related to various factors such as genetics, pre-disposed metabolic disorders, and immunologic factors. Thankfully, to date, there have been accumulating research efforts and, as a result, different classes of potent drug candidates have been discovered. In addition, there have also been various attempts to explore pharmaceutical strategies to improve the druggability of drug candidates. In this review, we provided a brief overview of the drug candidates that have undergone clinical trials. In the latter part, strategies for developing better drugs are discussed.

Funder

National Research Foundation of Korea

NRF

Basic Science Research Program through the National Research Foundation of Korea

Publisher

MDPI AG

Subject

Pharmaceutical Science

Reference179 articles.

1. Nonalcoholic fatty liver disease;Clark;Gastroenterology,2002

2. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention;Younossi;Nat. Rev. Gastroenterol. Hepatol.,2018

3. The relationship between glycaemic control and non-alcoholic fatty liver disease in Nigerian type 2 diabetic patients;Afolabi;J. Natl. Med. Assoc.,2018

4. Association of NAFLD with diabetes and the impact of BMI changes: A 5-year cohort study based on 18,507 elderly;Liu;J. Clin. Endocrinol. Metab.,2017

5. Non-alcoholic fatty liver disease–a global public health perspective;Younossi;J. Hepatol.,2019

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3